Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

por Wei, Huafeng, Zhao, Likun, Hellstrom, Ingegerd, Hellstrom, Karl Erik, Guo, Yajun
Publicado 2014

Tumor Regression and Cure Depends on Sustained Th1 Responses

por Dai, Min, Hellstrom, Ingegerd, Yip, Yuen Y., Sjögren, Hans Olov, Hellstrom, Karl Erik
Publicado 2018

Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands

por Yi, Ling, Zhao, Yanlin, Wang, Xiaojue, Dai, Min, Hellström, Karl Erik, Hellström, Ingegerd, Zhang, Hongtao
Publicado 2014

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models

por Ying, Liu, Tuve, Sebastian, Persson, Jonas, Beyer, Ines, Yumul, Roma, Li, ZongYi, Tragoolpua, Kajornsak, Hellström, Karl-Erik, Roffler, Steve, Lieber, André
Publicado 2011

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

por Wei, Huafeng, Zhao, Likun, Li, Wei, Fan, Kexing, Qian, Weizhu, Hou, Sheng, Wang, Hao, Dai, Min, Hellstrom, Ingegerd, Hellstrom, Karl Erik, Guo, Yajun
Publicado 2013